Meningococcal vaccines: Current state and future outlook.

Neisseria meningitidis infections are a major public health problem worldwide. Although conventional approaches have not led to development of a serogroup B meningococcal vaccine, a new technique based on genome sequencing has created new perspectives. Recently, a universal serogroup B meningococcal vaccine, Bexsero(®), was licensed in Europe, Australia and United States, following several clinical studies demonstrating its immunogenicity and safety. Availability of this vaccine could contribute positively to human health, by significantly reducing the incidence of meningococcal infections. However, unfavorable cost-effectiveness analysis means that routine vaccination is not currently recommended. Another serogroup meningococcal vaccine, Trumemba(®), was also recently licensed in United States. Like any drug, Bexsero(®) and Trumemba(®) will require close observation to assess their impact on meningococcal epidemiology.

Design and optimization of some collagen-minocycline based hydrogels potentially applicable for the treatment of cutaneous wound infections.

Topical delivery systems for the treatment of different infected cutaneous wounds based on natural biopolymers are widely studied. The development of some topical hydrogels with type I collagen and minocycline by the experimental design technique, based on response surface methodology and Taguchi's approach, and the evaluation of their kinetic properties is presented. The concentrations of polymer, drug and cross-linking agent were selected as independent variables for the face centered composite design and low, medium and high concentration as variation levels for each factor. Minocycline kinetic release was investigated using a modified Franz diffusion cell. The drug release followed the Higuchi model. Three formulations having optimal minocycline release profiles were selected. They can be used as potential drug topical release systems for the treatment of infected cutaneous tissue.

Development and use of a computer system in a radiotherapy department: SISGRAD.

SISGRAD, the interactive computer system of the Antoine-Lacassagne Cancer Center Radiotherapy Department, has been operational since January 1982. It completes the computerized dosimetry system installed several years earlier and is fully integrated with the institution's central network. SISGRAD is in charge of surveillance of the radiotherapy treatments given by the Center's three radiotherapy units (1400 patients per year); it is also used for administrative purposes in the Department and physically connects all of the Department's operating stations. SISGRAD consists of a series of microcomputers connected to a common mass memory; each microcomputer is used as an intelligent console. SISGRAD was developed to guarantee that the treatments comply with prescriptions, to supply extemporaneous dosimetric data, to improve administrative work, and to supply banks with data for statistical analysis and research. SISGRAD actively intervenes to guarantee treatment quality and helps to improve therapy-related security factors. The present text describes the results of clinical use over a 4-year period. The consequences of integration of the system within the Department are analyzed, with special emphasis being placed on SISGRAD's role in the prevention and detection of errors in treatment prescription and delivery.

[Determination of beta2-microglobulin in breast, lung, colorectal and ENT carcinoma (author's transl)]. / Dosage de la beta2-microglobuline dans les cancers du sein, du poumon, du côlon et de la sphère ORL.

Significant increase of plasma level beta2-microglobulin in cancer patients (breast, bronchus, colorectal and ENT) occurs rarely. More, the highest levels observed are within the range of non malignant diseases. We cannot assume that beta2-microglobulin assay will be useful as tumor marker.